Our Keynote head and neck cancer clinical trials are studying pembrolizumab to see if it may help patients with head and neck cancer. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
Clinical trials for head and neck cancer are underway and currently enrolling patients. If you have patients with head and neck cancer, you may want to consider a Keynote trial. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma||412||Head and Neck Neoplasms||Phase 3||Recruiting|
|Study of Pembrolizumab in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma||629||Squamous Cell Carcinoma||Phase 2||Recruiting|
|Pembrolizumab Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer||040||Head and Neck Squamous Cell Cancer||Phase 3||Active, not recruiting|
|A Study of Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck||048||
||Phase 3||Active, not recruiting|
|Study of MK-3475 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy||055||Head and Neck Squamous Cell Carcinoma||Phase 2||Active, not recruiting|
|Study of Pembrolizumab in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer||122||Nasopharyngeal Neoplasms||Phase 3||Active, not recruiting|